Sunnybrook Research Institute
Recipient of the 2017 UFCW Canada Award for Leukemia Research
Improving Ibrutinib therapy in chronic leukemia by targeting janus kinases
Chronic lymphocytic leukemia (CLL) is the commonest leukemia in Canada and is often fatal. A new drug called Ibrutinib has been of great help to CLL patients but does not cure them. Dr. Spaner's group has found that CLL cells are kept alive in the presence of Ibrutinib by proteins called cytokines. Learning the best way to block the effects of cytokines should improve the lives of patients on Ibrutinib.